share_log

Trinity Biotech Says It Is Targeting Approximately $20M Of Annualized Run-rate EBITDA On Annualized Run-rate Revenues Of Approximately $75M By Q2, 2025

Moomoo 24/7 ·  Apr 4 07:45

The company said this outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment